An observational study in Asthma, Mild Asthma and Moderate Asthma, sponsored by Societa Italiana di Pneumologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Societa Italiana di Pneumologia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.
Among the 177 studies in Asthma with a site in Italy, this one has the largest planned enrollment of the 47 observational ones that give a count, is one of 15 that started in 2021, is one of 47 observational ones, reaches primary completion later than 0 of the 28 other live ones, and was the 119th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 6+
Generate Biomedicines · Sites in Italy, United States, Argentina and 16 more countries
Ages 12–80
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–17
Pfizer · Sites in Italy, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Italy, United States, Argentina and 18 more countries
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 15 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 402 across the 130 interventional studies, 152 across the 47 observational. Of the 136 that completed or were terminated, 66 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 177 have an industry lead sponsor. The 10 most frequent:
Societa Italiana di Pneumologia is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Societa Italiana di Pneumologia has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT04442646Istituti Clinici Scientifici Maugeri SpARole of "Asthma School" in Disease Management | 2026-12-15 |
| NCT06625216Società Italiana di Allergologia, Asma e Immunologia ClinicaSevere Asthma Network Italy | 2027-02-17 |
Add all 10 to your calendar (.ics) → With an account.
Among the 177 studies in Asthma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this registry aims is to collect a large number of patients with mild and moderate asthma in a real-word conditions for a perspective observation of epidemiological evolution of the disease in relation to the therapeutic interventions available currently and in the near future.
To represent real-world mild moderate Italian asthmatics, all adults with diagnosed asthma by specialist, according GINA (Global Initiative for Asthma) document, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her general practitioners will be delivered.
Subjects follow up will be scheduled according with GINA document and center plan (6 or 12 months follow up visit).
To represent real-world mild moderate Italian asthmatics, all adults with diagnosed asthma by specialist, according GINA document, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her GPs will be delivered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A cluster-based, real world, cross-sectional perspective, observational cohort study
Perspective observation of epidemiological evolution of mild and moderate asthma (rate of asthmatic patients transitioned to a more severe stage according Global Initiative for Asthma \[GINA\] document)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Real life assessment of control, exacerbation and PROs in patients treated with different drugs and schedule
Real-life assessment of asthma control over time (Asthma Control Test and Asthma Control Questionnaire scores), exacerbation rate over time (n/year) and patient-reported outcomes (e.g., quality of life, patient engagement, disease awareness) from groups treated with different drugs and schedules (questionnaire score)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Asthma control in pregnant women
Asthma control in pregnant women by means of a specific application for android- and iOS-based smartphones, in comparison with the traditional current management
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Burden of OCS in mild and moderate asthma
Burden of oral corticosteroids in mild and moderate asthma (mg/year)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
SABA use in mild and moderate asthma
SABA use in mild and moderate asthma (canisters/year)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Influence of infections and vaccinations on disease outcomes and progression
Influence of infections and vaccinations on disease outcomes and progression (rate of progression; questionnaire score)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Influence of upper airway disease on disease outcomes and progression
Influence of upper airway disease on disease outcomes and progression (rate of progression; questionnaire score)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Impact of inhalation techniques and smart inhalers on disease outcomes and progression
Impact of inhalation techniques and smart inhalers on disease outcomes and progression (inhalation error/asthma control score; inhalation error/rate of progression)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Environmental exposure influences on disease outcome and progression
Environmental exposure influences on disease outcome and progression (PM10/rate of progression)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Evolution of inflammatory patterns over time
Evolution of inflammatory patterns over time and their relationships to disease outcomes and progression (published biomarker value/asthma control; published biomarker value/rate of progression)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Role of smoking and life style in lung function and disease progression
Role of smoking and life style in lung function and disease progression (pack year/disease progression)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Patients reported outcomes over time
Patients reported outcomes over time (score according validated questionnaires)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Patient awareness and engagement in mild and moderate asthma
Patient awareness and engagement in mild and moderate asthma (questionnaire score)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Impact of digital therapy on disease management and outcomes
Impact of digital therapy on disease management and outcomes (canister/year and dose/year)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Direct, indirect, and intangible costs of mild and moderate asthma
Direct, indirect, and intangible costs of mild and moderate asthma (EU/disease severity)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Cost-efficiency of mild/moderate asthma treatments and management plans
Cost-efficiency of mild/moderate asthma treatments and management plans (cost/year)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
Sociodemographic issues related to disease progression and burden
Sociodemographic issues related to disease progression and burden (age, sex, education, employment/rate of progression)
Time frame: through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in May 2021, 0 months.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 0 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Societa Italiana di Pneumologia